

tory potency) can be retrieved from libraries within the simulator. However, the information on each patient (ie, demography, physiology, genetics, enzyme abundances and activity, level of plasma proteins, kidney function, various drugs taken and their dosage information) are also required. Some of these are not available routinely and hold the key to “Clinical Oriented” applications (eg, in iPad and so on).

Disclosure of Interest: A. Rostami-Hodjegan: shareholder of Certara, Diurnal, and Zilico; grant/research support from a consortium of pharmaceutical companies; and other: part-time secondee to Simcyp (Certara).

DEVELOPING A STANDARDISED PRESCRIPTION CHART TO REDUCE ERROR

P. Routledge*

Pharmacology, Therapeutics and Toxicology, Cardiff University, Cardiff, United Kingdom

Summary: Unfamiliarity is an important contributor to error, including medication errors, some of which result in adverse events. Paper-based inpatient prescription charts differ in different hospitals, and medical trainees move around health care systems, so they may be unfamiliar with such charts initially.

Standards for the design of inpatient prescriptions charts have recently been agreed by the Academy of Medical Royal Colleges in the United Kingdom.¹ In several studies, standardization of prescribing documents has been associated with significantly reduced medication errors in adults in Australia,² as well as in some aspects of pediatric medicine. The introduction of a single inpatient prescription chart in Wales in 2004³ and its subsequent continuing development will be described. The training resources developed to support the chart will also be discussed.

Standardization of prescribing standards, of acceptable abbreviations, and standardized training in prescribing can also all contribute to a reduction in medication errors and associated adverse events, including when electronic rather than paper-based prescriptions are written.

Disclosure of Interest: None declared.

References

1. Academy of Medical Royal Colleges 2011. Standards for the design of hospital in-patient prescription charts. <http://www.aomrc.org.uk/publications/reports-a-guidance.html>. Accessed 10/07/2013.
2. Coombes ID, Reid C, McDougall D, et al. Pilot of a national inpatient medication chart in Australia: improving prescribing safety and enabling prescribing training. *Br J Clin Pharmacol*. 2011;72:338–349.
3. Routledge PA. A national in-patient prescription chart: the experience in Wales 2004–2012. *Br J Clin Pharmacol*. 2012;74:561–565.

THE INDIVIDUALISATION OF CANCER THERAPY IN ORGAN DYSFUNCTION

M. Rudek*

Oncology, Johns Hopkins University, Baltimore, Maryland

Summary: Cancer patients with adequate hepatic or renal function are typically studied during drug development. The majority of anticancer agents are cleared by via hepatic or renal mechanisms. Therefore, dose adjustments would be anticipated in patients with organ dysfunction. However, when a drug is approved, dosing modification guidelines are often lacking for patients who have varying

degrees of hepatic or renal dysfunction, especially moderate or severe dysfunction. In clinical practice, oncologists may start therapy with an empirically derived lower starting dose due to the perception that a patient with organ dysfunction would have poorer tolerability due to increased toxicity. The presentation will summarize: (1) A brief historical perspective of individualization of cancer therapy in organ dysfunction; (2) pathophysiology of organ dysfunction in cancer patients; (3) barriers to the conduct of clinical trials in this population; and (4) recent examples of dosing recommendations for anticancer agents.

Disclosure of Interest: M. Rudek: grant/research support from Celgene.

GENE THERAPY APPROVAL PROCESS AT EMA

S. Ruiz*

Spanish Medicines Agency (AEMPS), Madrid, Spain

Summary: In addition to the increasing number of biological and biotechnological medicinal products available for different clinical indications, the development of gene- and cell-based products offer alternative approaches for the prevention and treatment of human diseases. An increasing number of gene therapy and somatic cell therapy products are already in clinical development for the treatment of inherited diseases, cancer, diabetes, Parkinson's disease, and other neurodegenerative disorders. As gene and cell therapy products are presented as having properties for treating or preventing diseases in human beings, or that they may be used in or administered to human beings with a view to restoring, correcting, or modifying physiological functions by exerting principally a pharmacologic, immunologic, or metabolic action, they are considered biological medicinal products within the meaning of Annex I to Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use.

Regulation (EC) 1394/2007 introduces additional provisions to those laid down in Directive 2001/83/EC and regulates advanced therapies that are intended to be placed on the market in the EU Member States and either prepared industrially or manufactured by a method involving an industrial process. However, ATMP “prepared on a non-routine basis according to specific quality standards, and used within the same Member State in a hospital under the exclusive professional responsibility of a medical practitioner, in order to comply with an individual medical prescription for a custom-made product for an individual patient” are excluded. EU Member States are currently developing the rules to apply to these products to guarantee their quality and safety.

A review of gene therapy medicinal products that have applied for marketing authorization application through the European Medicines Agency will be presented.

Disclosure of Interest: None declared.

DOPING IN SPORT: THE BIOMARKERS ARE THE BEST TOOLS TO MEASURE ITS PREVALENCE AND TO ESTABLISH THE INDIVIDUAL MONITORING OF THE ATHLETES

M. Saugy^{1,2,3,4*}

¹Swiss Laboratory for Doping Analyses, University Center of Legal Medicine, Geneva; ²Swiss Laboratory for Doping Analyses, University Center of Legal Medicine; ³Centre Hospitalier Universitaire Vaudois; and ⁴University of Lausanne, Lausanne, Switzerland

Summary: The athlete biological passport (ABP) is an individual and longitudinal monitoring of biomarkers potentially linked to doping.

This came naturally with the implementation of tests out of the competition period of the athletes. For an athlete, it has been observed that the homeostasis of biosynthesis and metabolism of endogenous hormones was not disturbed by sports activity but of course will be influenced by the intake of similar substances. Actually, the passport has been defined as an individual and longitudinal observation of biomarkers. These markers need to belong to the biological cascade influenced by the application of forbidden hormones or, more generally, affected by biological manipulations that can improve the performance of the athlete.

Nowadays, only the hematologic passport of an athlete has been officially set up. This is a statistical representation of the longitudinal follow-up of some blood biomarkers. This individual and longitudinal follow-up of blood parameters is of interest because the intraindividual variability is lower than the corresponding inter-individual variability. Among the key points for the implementation of the ABP is its possibility to resist to the legal and scientific challenges. The ABP should be implemented in the most possible transparent way in the process and with the necessary independence between planning, interpretation, and result management of the passport.

To reach this transparency and efficiency, a new major actor has been introduced in the system to create a framework of independence: The athlete Passport Management Unit (APMU). The World Antidoping Agency (WADA) did implement new dedicated technical documents associated with the passport (hematologic module). This was done to allow the correct implementation of a profile that can resist any scientific or legal critics in following strictly some steps in the chain of production of the results and in the management of the interpretation of the passport.

Disclosure of Interest: None declared.

NEW INSIGHTS INTO THE MECHANISMS OF DIOXIN TOXICITY IN HUMANS

J.-H. Saurat*

Offices R&D, Geneva, Switzerland

Summary: Several million people are exposed to dioxin and dioxin-like compounds, primarily through food consumption. Skin lesions historically called “chloracne” are the most specific sign of abnormal dioxin exposure and classically used as a key marker in humans. We followed up for 5 years a man who had been exposed to the most toxic dioxin, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), at a single oral dose of 5 million-fold more than the accepted daily exposure in the general population. We adopted a molecular medicine approach, aimed at identifying appropriate therapy. Skin lesions, which progressively covered up to 40% of the body surface, were found to be hamartomas, which developed parallel to a complete and sustained involution of sebaceous glands, with concurrent transcriptomic alterations pointing to the inhibition of lipid metabolism and the involvement of bone morphogenetic proteins signaling. Hamartomas created a new compartment that concentrated TCDD up to 10-fold compared with serum and strongly expressed the TCDD-metabolizing enzyme cytochrome P-450 1A1, thus representing a potentially significant source of enzymatic activity, which may add to the xenobiotic metabolism potential of the classical organs such as the liver. This historical case provides a unique set of data on the human tissue response to dioxin for the identification of new markers of exposure in human populations. The herein discovered adaptive cutaneous response to TCDD also points to the potential role of the skin in the metabolism of food xenobiotics.

Key Words: dioxin, toxicity, skin, hamartoma, morphology

Disclosure of Interest: None declared.

THE NEW ZEALAND CENTRE FOR ADVERSE DRUG REACTIONS MONITORING: A SOURCE OF PRACTICE-BASED EVIDENCE

R.L. Savage*

Preventive and Social Medicine, University of Otago, Dunedin, New Zealand

Summary: In New Zealand, there has been discussion around the value of evidence-based medicine in primary care and the case for complementary practice-based evidence that could feed back into the evidence from clinical trials on the generality and applicability of the interventions in the “real-life” context.¹ It is clear that databases of adverse drug reaction (ADR) reports are, in fact, a source of practice-based evidence.

In 1965, New Zealand became 1 of the first countries to collect and assess reports submitted by health professionals of suspected ADRs in individual patients. This collection is the database of the Centre for Adverse Reactions Monitoring (CARM) based in the New Zealand Pharmacovigilance Centre. Distinctive features of the New Zealand database are the high proportion of well-documented reports, and, frequently, the highest reporting rate/population in international comparisons. New Zealand was also a founding member of the WHO International Drug Monitoring Programme.

Databases of ADRs were established to generate hypotheses to be tested about previously unrecognized adverse reactions and interactions. Occasionally, they contain sufficient evidence in themselves. They can also identify prescribing practices that might increase the potential for ADRs to occur. They can feed back into guidelines the consequences of their use or nonuse and identify unexpected problems that arise with issues such as pathways to accessing funded medicines. Well-documented ADR reports can also highlight risk factors, thus providing a valuable contribution to risk/benefit assessments in individual patients. Examples from the New Zealand database and from international collaboration will be discussed that support the use of ADR reports as practice-based evidence in a nonhierarchical system in which case reports and case series, observational studies, and randomized clinical trials contribute in a flexible relationship depending on the issue under investigation.

One of the major challenges in optimizing the contribution of ADR databases to clinical practice is the provision of feedback that aids prescribing and also stimulates the quality as well as quantity of reporting.

Disclosure of Interest: None declared.

Reference

1. Parsonson B. The case for practice-based evidence to support evidence-based practice. *J Prim HealthCare*. 2012;4:98-99.

RISK PERCEPTION AMONG HEALTH CARE PROFESSIONALS AND THE PUBLIC: EXPERIENCE FROM REGIONAL MEDICINES INFORMATION AND PHARMACOVIGILANCE CENTRES IN NORWAY

J. Schjøtt^{1,2,3*}

¹Section of Clinical Pharmacology, Laboratory of Clinical Biochemistry, Haukeland University Hospital; ²Department of Clinical Science, University of Bergen; and ³Regional Medicines Information and Pharmacovigilance Centre (RELIS Vest), Haukeland University Hospital, Bergen, Norway

Summary: Risk perception associated with medicines information affects drug therapy and drug adherence. One problem is inconsistencies between sources providing medicines information, which give